Both Vanderbilt Medical Center and Williamson Medical Center have joined the Healthcare Worker Exposure Response and Outcomes (HERO) clinical trial, a federally-supported research effort investigating the effectiveness of plaquenil hydroxychloroquine in preventing the contraction of COVID-19. Sponsored by Duke University and in collaboration with the Patient-Centered Outcomes Research Institute (PCORI), the investigators hope to determine if the experimental treatment can help prevent the virus.
Vanderbilt & Williamson Medical Center of TN Join HERO Study
You may also like:
Williamson Medical workers to participate in COVID-19 drug trial
National health care registry to help prepare for future medical crisis The COVID-19 outbreak in the U.S. has left nearly every American scrambling for a plan. A national study …
Williamson Medical Center, Vanderbilt chosen as first participants in state for new COVID-19 prevention drug trial
As the number of coronavirus cases continues to climb in the United States and in Tennessee, with the volunteer state confirming a total of 4,138 cases as of Wednesday, drug trials have been launched across the country, all with the goal of discovering prevention and treatment methods for those infected with COVID-19…
Williamson Medical Center employees participating in coronavirus drug trial
As of this week, Williamson Medical Center employees can sign up for a clinical trial drug that could help their resistance to the coronavirus…
Interested in Enrolling?
If you are interested in learning more about a clinical trial, please click on enroll now and provide your information. Our staff will be happy to contact you to provide additional details and determine if you are suitable to participate in one of our active clinical trials. There is no obligation, and your information will be kept confidential.